Preventing neutropenia after cancer treatment with mecapegfilgrastim injections

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, observational real-world study follows adults with solid tumors who receive mecapegfilgrastim injections as prophylaxis against neutropenia after cancer treatment. Clinicians give mecapegfilgrastim for primary or secondary prevention when patients are judged to be at high or increased risk of febrile neutropenia or have had prior neutropenic events. The study collects safety and effectiveness data—such as rates of neutropenia, febrile neutropenia, treatment delays, and adverse events—without changing routine clinical care. Data are gathered at participating sites, primarily Hebei Medical University Fourth Hospital, to reflect everyday clinical practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Patients with malignant tumors confirmed by histopathology or cytology; 2. Age ≥18 years old; 3. After referring to various guidelines, the researchers believed that the subjects:

  1. Patients who are currently receiving treatment regimens with high FN risk;
  2. Patients who are currently receiving treatment regimens for moderate FN risk and meet any one of the factors that increase the risk coefficient;
  3. FN or dose-limiting neutropenia events have occurred in previous treatment cycles;
  4. In addition to the above, the researchers believe that the medication regimens will cause neutropenia and affect the normal treatment of the subjects; 4. Researchers believe that they can benefit; 5. Voluntarily participate in this clinical trial and be able to sign the informed consent form in person.

Exclusion Criteria:

* 1\. Those who are allergic to the test drug； 2. Those with mental or neurological disorders who are unable to cooperate； 3. Pregnant or lactating female patients; Women of childbearing age who refuse to take contraceptive measures； 4. Those who were considered unsuitable for inclusion by the researchers.

Where it's running

• HebeiMuFH
  Shijiazhuang, Hebei, China Recruiting

Study contacts

• Study coordinator: cheng doctor
• Email: jiekejaker@sina.com
• Phone: 18531117159

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Low-dose liposomal amphotericin B to prevent invasive fungal infections in neutropenic children

  This study tests whether giving a fixed low dose of liposomal amphotericin B can prevent invasive fungal infections in children aged 3–17 who are severely neutropenic after hematopoietic stem cell transplantation or similar high-risk conditions.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Haikou, Hainan · NCT07725263

• G-CSF–fusion protein to prevent chemotherapy neutropenia in children with sarcoma

  This trial tests Albipagrastim alfa (QLC2519) in children with sarcoma to see if it helps prevent chemotherapy-induced neutropenia.

  Recruiting Phase 2 Qilu Pharmaceutical Co., Ltd. · Beijing · NCT07724756

• Preventing G-CSF bone pain with diosmin-hesperidin and loratadine

  We will test whether diosmin-hesperidin, loratadine, or both can prevent bone pain from G-CSF in adults with leukemia or lymphoma.

  Recruiting Alexandria University · Alexandria · NCT07300735

• Home blood count monitoring to diagnose cyclic versus severe congenital neutropenia

  This test uses a home device called Athelas One to measure white blood cell and neutrophil counts in people with known ELANE mutations to see if daily home numbers can diagnose cyclic neutropenia and tell it apart from severe congenital neutropenia.

  Recruiting Early Phase 1 University of Washington · Seattle, Washington · NCT07066085

• Examining the NUDT15 gene's role in inflammatory bowel disease in Taiwan

  This study looks at how the NUDT15 gene affects children with inflammatory bowel disease in Taiwan to see if it can help improve their treatment.

  Recruiting National Taiwan University Hospital · Taipei · NCT06913998

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.